News in Brief

The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure.

There is currently no drug approved worldwide for the treatment of sudden hearing loss. However, preclinical and clinical phase-1-studies with the innovative drug candidate AC102 have been promising. AudioCure Pharma, a Berlin-based start-up supported by investors, is driving forward research and development. Now, InfectoPharm, a successful medium-sized company, is joining as a new and essential competence partner.

Die AudioCure Pharma GmbH aus Berlin gewinnt mit ihrem neuartigen Wirkstoff AC102 den Innovationspreis Berlin Brandenburg 2024. Im Falle einer Zulassung als Medikament könnte AC102 einen wichtigen Fortschritt in der Behandlung des Hörsturzes darstellen, für den es bisher keine zugelassene und nachweislich wirksame Behandlungsoptionen gibt.

Berlin-based start-up AudioCure Pharma has enrolled more than 50% of the planned patients in its ongoing Phase 2 clinical trial. The aim of the study is to test the efficacy of the new compound AC102 for the treatment of sudden hearing loss. As sudden hearing loss is usually treated with non-specific corticoids that are not approved for this indication or for which there is no clear evidence of efficacy, there is an urgent need for new therapies.

A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models. This is the key finding of a recent publication in the prestigious scientific journal PNAS by the Berlin-based start-up AudioCure Pharma.

High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss. Moreover, they are associated with more side effects and significantly worse outcomes for speech recognition and tinnitus perception. Additionally, 60% of patients treated with the standard dose had not fully recovered by the end of the study.

AC102-201: A Phase 2 Clinical Trial Comparing the Efficacy of AC102, an Innovative Small Molecule, to Corticosteroids in Patients with Idiopathic Sudden Sensorineural Hearing Loss Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will present the AC102-201...

AudioCure is pleased to announce that it has been awarded for their innovative therapeutic small molecule, AC102, by the Hearing Technology Innovator Awards™, honoring technological innovation and accomplishments in the hearing industry.

České Budějovice, 31st May – 2nd June 2023: 84. Kongres České́ společnosti Otorinolaryngologie a chirurgie hlavy a krku ČLS JEP   The Czech Society of Otorhinolaryngology and Head and Neck Surgery establishes recommended practices in the field and ensures...